Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.

Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P.

PLoS One. 2013 Sep 11;8(9):e75099. doi: 10.1371/journal.pone.0075099.

Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease.

Quintanilla RA, Jin YN, von Bernhardi R, Johnson GV.

Mol Neurodegener. 2013 Dec 11;8:45. doi: 10.1186/1750-1326-8-45.

Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.

Hart EP, Dumas EM, Giltay EJ, Middelkoop HA, Roos RA.

J Huntingtons Dis. 2013;2(2):137-47. doi: 10.3233/JHD-130059.

Joint recognition-expression impairment of facial emotions in Huntington's disease despite intact understanding of feelings.

Trinkler I, Cleret de Langavant L, Bachoud-Lévi AC.

Cortex. 2013 Feb;49(2):549-58. doi: 10.1016/j.cortex.2011.12.003.

Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers.

Silva AC, Almeida S, Laço M, Duarte AI, Domingues J, Oliveira CR, Januário C, Rego AC.

Mitochondrion. 2013 Nov;13(6):801-9. doi: 10.1016/j.mito.2013.05.006.

Huntington's disease gene expansion associates with early onset nonprogressive chorea.

Dosa L, Malandrini A, Di Donato I, Hladnik U, Meloni I, Mari F, Federico A.

Mov Disord. 2013 May;28(5):684. doi: 10.1002/mds.25443. No abstract available.

The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep.

Loh DH, Kudo T, Truong D, Wu Y, Colwell CS.

PLoS One. 2013 Jul 30;8(7):e69993. doi: 10.1371/journal.pone.0069993.

Clinical, laboratory and electrophysiological features of Morvan's fibrillary chorea.

Lee W, Day TJ, Williams DR.

J Clin Neurosci. 2013 Sep;20(9):1246-9. doi: 10.1016/j.jocn.2012.10.029.

Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression.

Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS; PREDICT-HD study group..

Neurobiol Dis. 2013 Jul;55:37-43. doi: 10.1016/j.nbd.2013.03.013.

A review of cognition in Huntington's disease.

Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA.

Front Biosci (Schol Ed). 2013 Jan 1;5:1-18. Review.

Defining the role of the Bcl-2 family proteins in Huntington's disease.

Sassone J, Maraschi A, Sassone F, Silani V, Ciammola A.

Cell Death Dis. 2013 Aug 15;4:e772. doi: 10.1038/cddis.2013.300. Review.

Morphometric analysis of Huntington's disease neurodegeneration in Drosophila.

Song W, Smith MR, Syed A, Lukacsovich T, Barbaro BA, Purcell J, Bornemann DJ, Burke J, Marsh JL.

Methods Mol Biol. 2013;1017:41-57. doi: 10.1007/978-1-62703-438-8_3.

Psychological well-being in persons affected by Huntington's disease: a comparison of at-risk, prodromal, and symptomatic groups.

Chisholm LZ, Flavin KT, Paulsen JS, Ready R.

J Health Psychol. 2013 Mar;18(3):408-18. doi: 10.1177/1359105312444646.

Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.

Kumar A, Sharma N, Mishra J, Kalonia H.

Eur J Pharmacol. 2013 Jun 5;709(1-3):1-12. doi: 10.1016/j.ejphar.2013.03.042.

Transcranial magnetic stimulation as a tool for understanding neurophysiology in Huntington's disease: a review.

Philpott AL, Fitzgerald PB, Cummins TD, Georgiou-Karistianis N.

Neurosci Biobehav Rev. 2013 Sep;37(8):1420-33. doi: 10.1016/j.neubiorev.2013.05.009. Review.